Shenzhen Myway Medical Technology
Innovative multimodal therapeutic devices for cardiac electrophysiology, renal denervation, and tumor ablation.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY100m | Series A | |
| Total Funding | 000k | ||
Related Content
PulseCare, founded in July 2021 and headquartered in Shenzhen, China, specializes in developing advanced multimodal therapeutic devices. Utilizing cutting-edge multimodal energy platform technology, PulseCare has introduced a range of products including nsPFA cardiac electrophysiology ablation, ultrasound renal denervation (RDN), and multimodal tumor ablation systems. These products are specifically designed to meet the diverse clinical needs for various medical conditions.
PulseCare primarily serves healthcare providers, including hospitals and specialized clinics, focusing on minimally invasive and non-invasive treatment options. The company operates in the medical device market, which is characterized by rapid technological advancements and stringent regulatory requirements.
PulseCare's business model revolves around the development, manufacturing, and distribution of its innovative therapeutic devices. Revenue is generated through the sale of these devices to healthcare institutions and through partnerships with medical professionals.
By continually advancing its technology and expanding its product portfolio, PulseCare aims to become a leading international player in the field of multimodal minimally invasive and non-invasive therapeutic devices.
Keywords: multimodal energy, cardiac electrophysiology, renal denervation, tumor ablation, minimally invasive, non-invasive, therapeutic devices, healthcare, medical technology, Shenzhen.